Pulse Biosciences Reports Q1 Financials with $18.6M Net Loss and $14.6M Quarterly Cash Burn
PLSE sits 62% above its 52-week low of $12.56.
Summary
Pulse Biosciences reported preliminary Q1 2026 financial results, including a net loss of $18.6 million and $14.6 million in cash used in operations, alongside updates on its clinical trials.
Key Events · Earnings and Guidance · PLSE
-
Q1 2026 Financial Results
Reported a preliminary net loss of $18.6 million on $0.4 million in product revenue for the first quarter ended March 31, 2026.
-
Cash Position and Burn
Ended Q1 2026 with $68.3 million in cash and cash equivalents, having used $14.6 million in operating activities during the quarter, indicating a runway of approximately 4.6 quarters.
-
Clinical Trial Progress
Reaffirmed accelerated enrollment for the NANOPULSE-AF trial (completion by early-Q4 2026) and NANOCLAMP-AF trial (completion by end of H1 2027).
Analysis · PLSE · Industrial Applications And Services
This 8-K provides official details on Pulse Biosciences' first-quarter financial performance, confirming a significant cash burn of $14.6 million, which reduces its cash and equivalents to $68.3 million. While the company has an existing ATM program and shelf registration for future capital raises, this burn rate implies a cash runway of approximately 4.6 quarters. The filing also reiterates previously announced accelerated enrollment timelines for its NANOPULSE-AF and NANOCLAMP-AF clinical trials, which are critical to its strategic focus on electrophysiology. Investors should monitor the company's cash management and progress in these pivotal trials.
At the time of this filing, PLSE was trading at $20.39 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $12.56 to $26.30. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.